<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466060</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6012</org_study_id>
    <nct_id>NCT03466060</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types</brief_title>
  <official_title>Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, randomized, double-masked, contralateral, 2 treatment x 2 period
      crossover, dispensing, five-visit study to gain clinical insights of the study lenses and
      solutions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Actual">June 19, 2018</completion_date>
  <primary_completion_date type="Actual">June 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Comfort</measure>
    <time_frame>Up to 2-Hours Post Lens Fitting</time_frame>
    <description>Subjective assessment of initial comfort was conducted using Visual Analogue Scale (VAS) of comfort. VAS of comfort consists of a vertical line which represents continuous scale from 0 (extremely uncomfortable) to 100 (extremely comfortable). VAS comfort was measured at 1-min, 5-min, 45-min, and 2-hours post-fit. The average comfort score for each solution was reported. This is a contralateral crossover, subject used the revitalens solution in one eye throughout the entire study therefore there are twice as many observations for revitalens compared to the other solutions.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Visual Acuity, Slit Lamp Biomicroscopy (Corneal Staining Assessment)</condition>
  <arm_group>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>senofilcon C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Opti-Free : RevitaLens / Clear Care : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Opti-Free : RevitaLens / RevitaLens : Clear Care</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clear Care : RevitaLens/ Opti-Free : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clear Care : RevitaLens / RevitaLens : Opti-Free</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Clear Care/ Opti-Free : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Clear Care / RevitaLens : Opti-Free</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Opti-Free / Clear Care : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Opit-Free / RevitaLens : Clear Care</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potential subjects must satisfy all of the following criteria to be enrolled in the
             study:

               1. Subjects must be 18-69 years of age (inclusive).

               2. Subjects must be habitual disposable hydrogel or silicone hydrogel (1-day,
                  2-week, or monthly replacement schedule) soft lens wearer in both eyes. Habitual
                  is defined as at least one (1) month of contact lens wear where the lenses are
                  worn for a minimum of six (6) hours per day and a minimum of five (5) days per
                  week.

               3. Subjects must have best corrected visual acuity of 20/25 (Snellen or equivalent)
                  or better in each eye.

               4. The subject's refractive sphere (vertexed) must be between -1.00 and -6.00 D in
                  each eye.

               5. The subject's refractive cylinder must be less than or equal to -1.00 D in each
                  eye.

               6. The subject must have normal eyes (i.e., no ocular medications or infections of
                  any type).

               7. Subjects must possess a functional/usable pair of spectacles and bring them to
                  the visit (only if applicable - to the investigators discretion).

               8. Subjects must read, understand, and sign the Statement of Informed Consent.

               9. Subjects must appear able and willing to adhere to the instructions set forth in
                  this clinical protocol.

                  Exclusion Criteria:

          -  Potential subjects who meet any of the following criteria will be excluded from
             participating in the study:

               1. Currently pregnant or breast-feeding.

               2. Diabetes

               3. Any ocular or systemic allergies or disease which may interfere with contact lens
                  wear (at the discretion of the investigator).

               4. Any systemic disease, autoimmune disease, or use of medication which may
                  interfere with contact lens wear (at the discretion of the investigator).

               5. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious
                  immunosuppressive disease (eg, HIV), by self-report.

               6. Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (RX
                  or OTC) that may interfere with contact lens wear (at the discretion of the
                  investigator).

               7. Grade 2 or greater corneal staining or conjunctival injection on the FDA scale.

               8. Clinically significant (Grade 3 or greater on the FDA scale) corneal edema,
                  corneal vascularization, or any other abnormalities of the cornea (excluding
                  corneal staining) which would contraindicate contact lens wear.

               9. Clinically significant (Grade 3 or greater on the FDA scale) tarsal abnormalities
                  which might interfere with contact lens wear.

              10. Any active ocular abnormalities/conditions that may interfere with contact lens
                  wear (at the discretion of the investigator).

              11. Any corneal distortion due to previous rigid gas permeable lens wear, surgery or
                  pathology.

              12. History of any ocular or corneal surgery (eg, RK, PRK, LASIK).

              13. Habitual contact lens wear modality as extended wear.

              14. Participation in any pharmaceutical or medical device related clinical trial
                  within 7 days prior to study enrollment.

              15. History of binocular vision abnormality or strabismus.

              16. Habitual wearers of rigid gas permeable lens within the past 3 months.

              17. Employees of investigational clinic (investigator, coordinator, and technician
                  etc.) or family members of employees of the investigational clinic by self-report
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern California College of Optometry</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Berkeley School of Optometry</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vue Optical Boutique</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Houston College of Optometry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <results_first_submitted>June 19, 2019</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03466060/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 130 subjects were enrolled into this study. Of those enrolled, 113 subjects were assigned and dispensed a study lens while, 15 subjects were screen failures and 2 subjects were assigned but not administered the Test article. Of those dispensed, 106 subjects completed the study while, 7 subjects were discontinued.</recruitment_details>
      <pre_assignment_details>Of those that completed the study, 78 subjects completed without a major protocol deviation impacting a primary endpoint.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etafilcon A-Opti-Free/Clear Care</title>
          <description>Subjects that were dispensed the etafilcon A lens throughout the entire study and received Opti-Free in one eye during first period and Clear in one eye during second period. During both periods Revitalens was received on the contralateral eye.</description>
        </group>
        <group group_id="P2">
          <title>Etafilcon A-Clear Care/Opti-Free</title>
          <description>Subjects that were dispensed the etafilcon A lens throughout the entire study and received Clear Care in one eye during first period and Opti-Free in one eye during second period. During both periods Revitalens was received on the contralateral eye.</description>
        </group>
        <group group_id="P3">
          <title>Senofilcon A-Opti-free/Clear Care</title>
          <description>Subjects that were dispensed the senofilcon A lens throughout the entire study and received Opti-Free in one eye during first period and Clear Care in one eye during second period. During both periods Revitalens was received on the contralateral eye.</description>
        </group>
        <group group_id="P4">
          <title>Senofilcon A-Clear Care/Opti-Free</title>
          <description>Subjects that were dispensed the senofilcon A lens throughout the entire study and received Clear Care in one eye during first period and Opti-Free in one eye during second period. During both periods Revitalens was received on the contralateral eye.</description>
        </group>
        <group group_id="P5">
          <title>Senofilcon C-Opti-Free/Clear Care</title>
          <description>Subjects that were dispensed the senofilcon C lens throughout the entire study and received Opti-Free in one eye during first period and Clear Care in one eye during second period. During both periods Revitalens was received on the contralateral eye.</description>
        </group>
        <group group_id="P6">
          <title>Senofilcon C-Clear Care/Opti-Free</title>
          <description>Subjects that were dispensed the senofilcon C lens throughout the entire study and received Clear Care in one eye during first period and Opti-Free in one eye during second period. During both periods Revitalens was received on the contralateral eye.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Test Lens Damage</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Grade 2 Conjunctivitis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lens Handling Difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects dispensed a study lens.</population>
      <group_list>
        <group group_id="B1">
          <title>Etafilcon A</title>
          <description>Subjects that wore the etafilcon A lens during the entire study.</description>
        </group>
        <group group_id="B2">
          <title>Senofilcon A</title>
          <description>Subjects that wore the senofilcon A lens during the entire study.</description>
        </group>
        <group group_id="B3">
          <title>Senofilcon C</title>
          <description>Subjects that wore the senofilcon C lens during the entire study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="9.41"/>
                    <measurement group_id="B2" value="27.7" spread="7.82"/>
                    <measurement group_id="B3" value="29.1" spread="10.52"/>
                    <measurement group_id="B4" value="28.3" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Island</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Comfort</title>
        <description>Subjective assessment of initial comfort was conducted using Visual Analogue Scale (VAS) of comfort. VAS of comfort consists of a vertical line which represents continuous scale from 0 (extremely uncomfortable) to 100 (extremely comfortable). VAS comfort was measured at 1-min, 5-min, 45-min, and 2-hours post-fit. The average comfort score for each solution was reported. This is a contralateral crossover, subject used the revitalens solution in one eye throughout the entire study therefore there are twice as many observations for revitalens compared to the other solutions.</description>
        <time_frame>Up to 2-Hours Post Lens Fitting</time_frame>
        <population>All subjects who successfully completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Revita- Lens</title>
            <description>All subject eyes that wore contact lenses pre-soaked in Revita-lens solution up to 2 hours regardless of the lens type.</description>
          </group>
          <group group_id="O2">
            <title>Clear Care</title>
            <description>All subject eyes that wore contact lenses pre-soaked in Clear Care solution up to 2 hours regardless of the lens type.</description>
          </group>
          <group group_id="O3">
            <title>Opti-Free</title>
            <description>All subjects eyes that wore contact lenses pre-soaked in Opit-Free solution up to 2 hours regardless of the lens type.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Comfort</title>
          <description>Subjective assessment of initial comfort was conducted using Visual Analogue Scale (VAS) of comfort. VAS of comfort consists of a vertical line which represents continuous scale from 0 (extremely uncomfortable) to 100 (extremely comfortable). VAS comfort was measured at 1-min, 5-min, 45-min, and 2-hours post-fit. The average comfort score for each solution was reported. This is a contralateral crossover, subject used the revitalens solution in one eye throughout the entire study therefore there are twice as many observations for revitalens compared to the other solutions.</description>
          <population>All subjects who successfully completed all study visits without a major protocol deviation.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-Minute Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" spread="11.74"/>
                    <measurement group_id="O2" value="92.4" spread="10.52"/>
                    <measurement group_id="O3" value="92.0" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Minute Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="10.17"/>
                    <measurement group_id="O2" value="93.4" spread="8.90"/>
                    <measurement group_id="O3" value="92.3" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 Minute Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" spread="9.48"/>
                    <measurement group_id="O2" value="93.7" spread="8.44"/>
                    <measurement group_id="O3" value="93.5" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Hour Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" spread="7.06"/>
                    <measurement group_id="O2" value="94.6" spread="7.32"/>
                    <measurement group_id="O3" value="94.3" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1-Minute Follow-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Posterior mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>5-minute Follow-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Posertior Mean Difference</param_type>
            <param_value>-2.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>45-Minute Follolw-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-2.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-Hour Follow-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-2.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1-Minute Follow-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5-Minute Follow-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>95% credible intervals are used to determine whether Test and Control solutions are statistically significantly different at each time point.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>45-Minute Follow-up Analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>95% credible intervals are used to determine whether Test and Control solutions are statistically significantly different at each time point.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2-Hour Follow-up Analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Posterior mean difference was calculated as Test-Control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 5-weeks per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etafilcon A - Revitalens</title>
          <description>Subjects that wore the etaiflcon A lens throughout the entire duration of the study and the revitalens solution in at least one eye throughout the entire study.</description>
        </group>
        <group group_id="E2">
          <title>Etafilcon A - Clear Care</title>
          <description>Subjects that wore the etaiflcon A lens throughout the entire duration of the study and the Clear Care solution in one duringeither period 1 or period 2 during the study.</description>
        </group>
        <group group_id="E3">
          <title>Etafilcon A- Optifree</title>
          <description>Subjects that wore the etaiflcon A lens throughout the entire duration of the study and the OPti-Free solution in one duringeither period 1 or period 2 during the study.</description>
        </group>
        <group group_id="E4">
          <title>Senofilcon A - Revitalens</title>
          <description>Subjects that wore the senfilcon A lens throughout the entire duration of the study and the revitalens solution in at least one eye throughout the entire study.</description>
        </group>
        <group group_id="E5">
          <title>Senofilcon A - ClearCare</title>
          <description>Subjects that wore the senofilcon A lens throughout the entire duration of the study and the Clear Care solution in one duringeither period 1 or period 2 during the study.</description>
        </group>
        <group group_id="E6">
          <title>Senofilcon A - Opti-Free</title>
          <description>Subjects that wore the senofilcon A lens throughout the entire duration of the study and the Opti-Free solution in one duringeither period 1 or period 2 during the study.</description>
        </group>
        <group group_id="E7">
          <title>Senofilcon C- Revitalens</title>
          <description>Subjects that wore the senofilcon C lens throughout the entire duration of the study and the revitalens solution in at least one eye throughout the entire study.</description>
        </group>
        <group group_id="E8">
          <title>Senofilcon C - ClearCare</title>
          <description>Subjects that wore the senofilcon C lens throughout the entire duration of the study and the Clear Care solution in one duringeither period 1 or period 2 during the study.</description>
        </group>
        <group group_id="E9">
          <title>Senofilcon C - OptiFree</title>
          <description>Subjects that wore the senofilcon C lens throughout the entire duration of the study and the Opti-Free solution in one duringeither period 1 or period 2 during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a contralateral crossover, subject used the revitalens solution in one eye throughout the entire study therefore there are twice as many observations for revitalens compared to the other solutions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Meredith Bishop, OD, MS, FAAO- Senior Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>904-443-1396</phone>
      <email>MBishop4@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

